Beyond Air Posts 107% Revenue Growth but Faces Regulatory and Financial Hurdles
Event summary
- Beyond Air reported a 107% year-over-year revenue increase to $7.7 million for fiscal 2026, with Q4 revenue up 66% to $1.9 million.
- The company is transitioning its fiscal year-end from March 31st to December 31st.
- Beyond Air announced revenue guidance of $8 million for calendar year 2026 and $16-$18 million for 2027, pending FDA approval of the second-generation LungFit PH system.
- Net loss attributable to common stockholders narrowed to ($33.2) million for fiscal 2026 from ($46.6) million in 2025.
The big picture
Beyond Air's strong revenue growth reflects increasing demand for its LungFit PH system, but the company faces significant challenges in securing FDA approval for its next-generation device. The transition to a December 31st fiscal year-end aligns with broader market expectations, while the company's ability to manage financial losses and cash burn will be key to maintaining investor confidence.
What we're watching
- Regulatory Approval
- The pace at which the FDA reviews and approves the second-generation LungFit PH system will determine Beyond Air's ability to expand its addressable market.
- Financial Stability
- Whether Beyond Air can sustain its revenue growth while managing high operating expenses and cash burn will be critical for long-term viability.
- Market Expansion
- How the company's international expansion and new hospital customer wins will impact its commercial execution and revenue guidance.